Updates

Abcam

May 2018

Investing in shares may lose you all or some of your money. Past performance is no indication of future performance. Some of the shares recommended here may be small company shares, which can be relatively illiquid and hard to trade and this makes such shares more risky than other investments.

One of a handful of stocks hitting highs is Abcam, which has moved solidly over £12.The company plays an important role in helping scientists find cures for cancer, alzheimers and other diseases through the sale, via an online catalogue, of its research-grade antibodies. Interims showed revenue growth of 9.8% (11.2% at constant currency) while pretax profit and eps grew 22% and 20% respectively to £39.3m and 15.5p.Core catalogue sales increased 11.5% to £105.2m. However, the main growth engine, recombinant antibody or RabMAb revenues (rabbit antibodies, which are superior to its original mouse antibodies because they bind to their targets better and send out a cleaner signal) grew 21% to £22.4m or almo ...

To access our archive of articles and to receive current issues you need to subscribe.

Subscribe now

Already a subscriber? Login

The Restaurant Group

Charter Court Financial

Abcam (September 2020)

Abcam (February 2019)

Abcam (September 2018)

Abcam (October 2017)

Abcam - Directors buy shares (May 2017)

Abcam - Supplier of antibodies to scientists enjoys 13-fold eps gains over 11 years! (November 2016)

Abcam (March 2013)

Abcam - Protect profit with stop-loss of 360p (December 2012)

Abcam - Trading "slightly ahead of expectations" (September 2012)

Abcam - Makes US$155m acquisition (May 2012)

Abcam - Acquisition takes Abcam into new US$6 bn market (December 2011)

Abcam - Results slightly ahead of expectations (September 2011)

Abcam - Acquires US-based firm (July 2011)

Abcam (June 2011)

Abcam (December 2010)

Abcam - Shares now Â£5 above tip price (October 2010)

Abcam - Shares soar after strong trading triggers broker upgrades (September 2010)

Abcam - Supplier of antibodies enjoys three eps upgrades in six months (May 2010)

With small companies there is an above average degree of risk compared to buying blue chips. Please be aware that we have not assessed the suitability of any of these investments for you. The newsletter simply states a personal view and diarises the editor’s investment decisions. Please speak to your stockbroker or other qualified individual to ascertain whether any of these companies mentioned would form useful additions to your own portfolios. Past performance is no indication of future success.

All material on this website is protected by copyright. You may use Information retrieved from the www.scsw.co.uk website for your own personal non-commercial use which means that you may not sell or copy this information to any third party without prior written consent. ISSN 1358-183X